• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Kelun-Biotech Initiates Phase III Trial For SAC-TMT with Keytruda

    PR NEWSWIRE

    FDA Approves Combo Therapy For Ineligible Bladder Cancer Patients

    INDPHARMAPOST

    Merck Gets EU Approval For First Subcutaneous Cancer Treatment,

    INDPHARMAPOST

    FDA Approves KEYTRUDA And KEYTRUDA QLEX™ With Padcev

    BUSINESSWIRE

    FDA Approves Padvec & Keytruda Combo For Bladder Cancer

    BUSINESSWIRE

    Kazia Therapeutics Hits Initial iCR in Metastatic TNBC

    PR NEWSWIRE

    Synthekine Reveals Positive Phase 1A/1B Trial Results

    BUSINESSWIRE

    Flare Therapeutics Presents FX-909 Ph1A Biomarker Analysis

    GLOBENEWSWIRE

    Eisai Shows Dedication To Advanced Endometrial Cancer Care

    PR NEWSWIRE

    Adagene Doses First Patient in Ph2 Muzastotug Combo Study

    GLOBENEWSWIRE

    Synthekine to Present STK-012 Combo Data in NSCLC at SITC 2025

    BUSINESSWIRE

    Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2

    BUSINESSWIRE

    EC Approves Keytruda Combo for PD-L1+Resectable Head&Neck Cancer

    BUSINESSWIRE

    Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer

    FIERCE PHARMA

    Welireg`s RCC Wins Could Pad Merck`s Post-Keytruda Sales

    FIERCE PHARMA

    FDA Prioritizes KEYTRUDA And KEYTRUDA QLEX Combo with Padcev

    BUSINESSWIRE

    MDNA11 Clinical Data From ABILITY-1 Study At ESMO 2025

    GLOBENEWSWIRE

    HCW Biologics Joins Virtual Investor Segment

    GLOBENEWSWIRE

    Keytruda, Lenvima Show Long-Term Survival Benefit in Cancer

    INDPHARMAPOST

    Flare Pharma Collaborates with Merck for Fx-909 and Keytruda

    GLOBENEWSWIRE

    KEYTRUDA® Shows Prolonged Survival Benefit In Some NSCLC Patients

    BUSINESSWIRE

    Immunos Therapeutics Shows IOS-1002 Promise In Advanced Solid

    PHARMIWEB

    Transgene & BioInvent’s BT-001 Shows Strong Antitumor Activity

    ACCESSWIRE

    Niios Pharma Presents NI-1801 Data For Platinum-Resistant Cancer

    PHARMIWEB

    IO Biotech Present Phase 3 Cylembio+ Keytruda Results

    GLOBENEWSWIRE

    Keytruda and Lenvima Show Long-Term Survival Benefit

    BUSINESSWIRE

    KEYTRUDA® Combo Reduces Progression Risk In Platinum-Resistant

    BUSINESSWIRE

    Keytruda, Padcev Cut Risk Of Death By 50% In MIBC Patient Subset

    FIERCE PHARMA

    ESMO: Merck Lays Out Keytruda`s Landmark Win In Ovarian Cancer

    FIERCE PHARMA

    Merck`s KEYNOTE-B96 Phase 3 Trial Meets Secondary Endpoint

    BUSINESSWIRE

    In Ovarian Cancer, Keytruda Follows PFS Win With Survival Showing

    FIERCE PHARMA

    Nucana Reports Positive NUC-3373 Data With Anti-PD-1 Therapy

    PHARMIWEB

    Bicara Pharma`s Ficerafusp Alfa Earns Breakthrough Designation

    GLOBENEWSWIRE

    Transgene, Bioinvent To Unveil BT-001, Oncolytic Virus Data

    ACCESSWIRE

    Moderna Claims Early Victory For Cancer Antigen In Melanoma

    BIOSPACE

    Moderna Unveils Positive Early Results For Cancer Antigen Therapy

    PHARMIWEB

    Nouscom Reveals NOUS-209 Immunotherapy Success In MSI-H Cancer

    GLOBENEWSWIRE

    Merck Expands Keytruda`s Role In Cancer Innovation To New Tumor

    INDPHARMAPOST

    Merck Advances Oncology Innovation At ESMO 2025

    PHARMIWEB

    Immutep Shares Update on Ph3 TACTI-004 Trial in Lung Cancer

    GLOBENEWSWIRE

    Bioinvent Starts BI-1206 Ph 2a Trial In Advanced NSCLC & Melanoma

    PR NEWSWIRE

    Tango Therapeutics To Unveil TNG260 Clinical Data at SITC 2025

    GLOBENEWSWIRE

    Eisai to Present 5-Year KEYNOTE-775 Data at ESMO 2025

    PR NEWSWIRE

    Incendia Therapeutics Showcases PRTH-101 In Thymic Cancers

    GLOBENEWSWIRE

    Astellas Showcases Innovations At ESMO 2025

    PR NEWSWIRE

    Judy Wang, Md Leads Manuscript On Enhancing Immunotherapy

    PR NEWSWIRE

    Microbiotica Completes Global Phase 1b of MB097 Trial Enrollment

    PHARMAWEB

    Io Biotech`s Advanced Melanoma Abstract Chosen For Esmo Congress

    GLOBENEWSWIRE

    Microbiotica Completes Recruitment for Intl Ph 1b Trial of MB097

    PHARMAWEB

    FDA Approves Merck`s Injectable Version of Blockbuster Keytruda

    REUTERS

    PDS Bio Achieves Extended Survival in Head and Neck Cancer Trial

    GLOBENEWSWIRE

    HCW Biologics Designates TRBC-Pembro Inhibitor As Lead Therapy

    GLOBENEWSWIRE

    Immutep to Present Ph2 EFTISARC-NEO Efti Data in Sarcoma at CTOS

    GLOBENEWSWIRE

    Adagene`s ADG126 Highlighted in Two Presentations at 2025 CSCO

    GLOBENEWSWIRE

    Akeso Completes Ph3 Enrollment for Ivonescimab in Biliary Cancer

    PR NEWSWIRE

    PDS Biotech`s Data VERSATILE-002 Phase 2 Head and Neck Cancer

    GLOBENEWSWIRE

    Padcev-Keytruda Combo Delivers Bladder Cancer `breakthrough`

    PRESS RELEASE

    Transgene, BioInvent to Share BT-001 Oncolytic Virus Data at ESMO

    ACCESSWIRE

    Immutep Abstracts Accepted for 2025 ESMO Congress

    GLOBENEWSWIRE

    NMPA Accepts sNDA for Ivonescimab Combo in Advanced Lung Cancer

    PR NEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.